ALM-488 is a peptide-dye conjugate designed to fluorescently highlight nerves in real time during surgery

Alume Biosciences Announces First Patient Dosed with ALM-488 in Phase 3 Pivotal Study in Patients Undergoing Head and Neck Surgery

[La Jolla, CA] — [August 23, 2022] – Alume Biosciences, Inc., a leader in the field of nerve-targeted diagnostics and therapeutics, today announced that the first patient has been dosed in a Phase 3 pivotal study of ALM-488 (NCT05377554). ALM-488 is a peptide-dye conjugate designed to highlight nerves with fluorescence in real time during surgery.

"The successful initiation of this Phase 3 pivotal study is another major milestone for Alume. It marks the final phase of clinical trial testing for ALM-488 for patients undergoing Head and Neck Surgery" said Brett Berman, MD, chief medical officer at Alume Biosciences. "This study underscores our commitment to improve intraoperative visualization of nerves, enabling Precision Surgery™".